Adoption of new agents and changes in treatment patterns for Hepatitis C: 2010-2014

American Journal of Managed Care

Volumn 22, Issue 6, 2016, Pages e224-e232

  Yao, Xiaoxi ^a   Sangaralingham, Lindsey R ^a   Ross, Joseph S ^c,d   Shah, Nilay D ^a,b   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

^b OPTUM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON; OLIGOPEPTIDE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEALTH INSURANCE; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DRUG EFFECTS; ECONOMICS; FACTUAL DATABASE; HEALTH CARE COST; HEPACIVIRUS; INSURANCE; MIDDLE AGED; PREDICTIVE VALUE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSURANCE CLAIM REVIEW; INTERFERONS; LOGISTIC MODELS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; UNITED STATES;

EID: 84975270363     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hepatitis C FAQs for health professionals. CDC website. http://www. cdc.gov/hepatitis/HCV/HCVfaq.htm. Updated May 23, 2016. Accessed June 2, 2016.
2. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol. 2003;13(1):57-68.
3. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-1069.
4. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24(1):38-47.
5. McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-593. doi: 10.1056/ NEJMoa0808010.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.
7. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002;97(1):149-155.
8. Bini EJ, Bräu N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100(8):1772-1779.
9. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32(suppl 1):151-156. doi: 10.1111/j.1478-3231.2011.02706.x.
10. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;349:g3308. doi: 10.1136/bmj.g3308.
11. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-523. doi: 10.1016/S0140-6736(13)62121-2.
12. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-1765. doi: 10.1016/S0140-6736(14)61036-9.
13. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493. doi: 10.1056/NEJMoa1316366.
14. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898. doi: 10.1056/NEJMoa1402454.
15. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887. doi: 10.1056/NEJMoa1214853.
16. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. HCV Guidelines website. http://hcvguidelines. org/sites/default/files/HCV-Guidance-April-2016-e1.pdf. Updated February 24, 2016. Accessed June 2, 2016.
17. Activists condemn Gilead for exorbitant price of its new hepatitis C drug. http://www.thebody.com/content/73462/activists-condemngilead-for-exorbitant-price-of-t.html. Published December 9, 2013. Accessed February 17, 2015.
18. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33(7):1187-1194. doi: 10.1377/hlthaff.2014.0038.
19. Real world health care experiences from over 150 million unique individuals since 1993. Optum. website. https://www.optum.com/content/dam/optum/resources/productSheets/5302-Data-Assets-Chart- Sheet-ISPOR.pdf. Accessed June 22, 2015.
20. Chen EY, Sclair SN, Czul F, et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol. 2013;11(8):1014-1020.e1-e2. doi: 10.1016/j. cgh.2013.03.032.
21. National income and product accounts tables. [section 1, Table 1.1.4. Price indexes for gross domestic product]. Bureau of Economic Analysis website. http://bea.gov/iTable/iTable.cfm?ReqID=9&step=1#re qid=9&step=3&isuri=1&903=4. Accessed March 19, 2015.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
23. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593-594. doi: 10.1001/jama.2014.8897.
24. FDA approves Olysio (simeprevir) in combination with sofosbuvir for genotype 1 chronic hepatitis C infection. Drugs.com website. http:// www.drugs.com/newdrugs/fda-approves-olysio-simeprevir-combination-sofosbuvir-genotype-1-chronic-hepatitis-c-infection-4107.html. Published November 2014. Accessed March 19, 2015.
25. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397-406. doi: 10.7326/M14-1336.
26. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407-419. doi: 10.7326/M14-1152.
27. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40(6):657-675. doi: 10.1111/apt.12871.
28. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162(9):619-629. doi: 10.7326/ M14-1313.